Charterhouse partners with Labomar's Founder to promote a voluntary tender offer on all the ordinary shares issued by Labomar S.P.A.
May 22, 2023
Charterhouse Capital Partners LLP (“Charterhouse”), one of the longest-established private equity firms operating in Europe, today announces that it has entered into an agreement to partner with Mr. Walter Bertin, founder and CEO of Labomar (or "the Company"), to promote, in concert, inter alia, with the Offeror and the same Mr. Walter Bertin, a voluntary tender offer aimed at delisting the Labomar shares.
Labomar is a full-service B2B innovation-driven CDMO, producing a wide range of nutraceutical products, medical devices and medical food supplements. The Company was founded in 1998 from the pharmacy of Mr. Bertin, and has quickly developed and grown to six facilities, 200 customers, 300 employees and 13 registered patents.
Labomar is headquartered in Treviso, Italy and is currently listed on the Italian stock exchange Euronext Growth Milan. It recently announced its FY 2022 results, generating €92m of sales and €17m of EBITDA.
Charterhouse has significant prior experience in the Healthcare sector through previous investments in Doc Generici, Cooper Consumer Health and SERB Pharmaceuticals.
The offer is subject to the applicable regulatory approvals and acceptance by the required number of shareholders. For an exhaustive and detailed description of the terms and conditions of the offer, please refer to the notice pursuant to Article 102 of the Italian Financial Act published, inter alia, on Labomar’s website and to the offer document which will be published within the terms provided for by law upon obtaining the relevant CONSOB's approval. Further announcements will be made during the tender offer period, in accordance with the applicable law.
Share this news on